Oleclumab
Oleclumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against 5'-nucleotidase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 3 | 8 | 1 | — | — | 11 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 3 | 1 | — | — | — | 3 | |
| Triple negative breast neoplasms | D064726 | 2 | 2 | — | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | 1 | — | — | — | 1 | ||
| Liposarcoma | D008080 | — | 1 | — | — | — | 1 | ||
| Hemangiosarcoma | D006394 | — | 1 | — | — | — | 1 | ||
| Pancreatic ductal carcinoma | D021441 | — | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
| Renal cell carcinoma | D002292 | — | 1 | — | — | — | 1 | ||
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OLECLUMAB |
| INN | oleclumab |
| Description | Oleclumab (INN; development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990016 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 5CRY01URYQ (ChemIDplus, GSRS) |
Target
Agency Approved
NT5E
NT5E
Organism
Homo sapiens
Gene name
NT5E
Gene synonyms
NT5, NTE
NCBI Gene ID
Protein name
5'-nucleotidase
Protein synonyms
5'-deoxynucleotidase, 5'-NT, CD73, Ecto-5'-nucleotidase, IMP-specific 5'-nucleotidase, Purine 5-Prime-Nucleotidase, Thymidylate 5'-phosphatase
Uniprot ID
Mouse ortholog
Nt5e (23959)
5'-nucleotidase (Q61503)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 219 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
92 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more